Methsuximide Catalog No.:M22869-C and was approved by the

and was approved by the FDA on February 25

⁶]tetradeca-1(14)

but not Na3VO4-

carazolol stimulated lipolysis

CNV 1014802

Methsuximide Catalog No.:M22869-C and was approved by theMethsuximide (or methsuximide, methosuximide, Celontin) is a succinimide anticonvulsant medication that is pharmacologically converted to its active metabolite N desmethylmethosuximide, a channel blocker that targets low threshold calcium currents. Methsuximide effectively suppressed the initial clonic seizures induced by Metrazol in rats and mice. Methsuximide was capable of protecting mice from tonic extensor seizures to supramaximal electroshock .